Global Biologics, Cell and Gene Legal Summit 2023

Global Biologics, Cell and Gene Legal Summit Returns 2023

Register Your Interest
Brussels, Belgium (BEL)
May 2023

“Join and create new innovative commercial and legal strategies, overcome market barriers, and take advantage of the growing opportunities in the biologic marketplace.”

Alistair Ren-Healey, Portfolio Director

2022 HIGHLIGHTS

  1. There are several blockbuster biologic drugs scheduled to loose their patent protection before 2025 – this creates an unique business opportunity the entrance of biosimilar products and other new therapies across the European marketplace.  
  2. “Putting the theories into practice” this is an exclusive event to overcome legal, IP and commercial challenges for a pharmaceutical, biotech company developing the next generation of biologic products 
  3. Stay ahead of the competition by discovering the IP, Market Access and Safe Harbour strategies for Cell & Gene Therapies
  4. Enhance the quality of the exchange by meeting your peers face to face, and enlarge your network which you cannot do in a virtual setting. 

Global Biologics Cell & Gene Legal Summit Testimonials

Biologics, Cell & Gene Legal Advisory Board

Author:

Karine Crepin

Global Head Vaccines Patents
GSK

Karine Crepin is the Vice President, Head of Vaccines Patents at GSK. She holds a Master Degree in Bioengineering (specialising in Biochemistry) and a PhD in molecular Biology. She is also a qualified European and Belgian Patent Attorney.

Before re-joining GSK in her current role, she worked for more than 9 years at Sanofi where she built a global team of more than 40 patent attorneys worldwide responsible for all patent matters relating to Sanofi Biologics including Vaccines and platform aspects, and before that for 15 years at GSK vaccines where she started her patent career.

Karine coordinates a large variety of patent related activities, from the protection of innovation to freedom-to-operate and post-grant administrative and judicial proceedings.

Karine Crepin

Global Head Vaccines Patents
GSK

Karine Crepin is the Vice President, Head of Vaccines Patents at GSK. She holds a Master Degree in Bioengineering (specialising in Biochemistry) and a PhD in molecular Biology. She is also a qualified European and Belgian Patent Attorney.

Before re-joining GSK in her current role, she worked for more than 9 years at Sanofi where she built a global team of more than 40 patent attorneys worldwide responsible for all patent matters relating to Sanofi Biologics including Vaccines and platform aspects, and before that for 15 years at GSK vaccines where she started her patent career.

Karine coordinates a large variety of patent related activities, from the protection of innovation to freedom-to-operate and post-grant administrative and judicial proceedings.

Author:

Fredrik Fredh

European Patent Attorney
Chr. Hansen

Fredrik is a qualified European Patent Attorney and experienced international IP strategist. Having completed academic studies of innovation and entrepreneurship processes, as well as IP law and management, he has a good grasp of various intellectual property rights (IPR).

Thanks to his many years as IP professional in the Pharma and Biotech industry, Fredrik has learnt to use this IPR toolbox to pursue his professional passion; maximizing return on investment for innovation.”

Fredrik Fredh

European Patent Attorney
Chr. Hansen

Fredrik is a qualified European Patent Attorney and experienced international IP strategist. Having completed academic studies of innovation and entrepreneurship processes, as well as IP law and management, he has a good grasp of various intellectual property rights (IPR).

Thanks to his many years as IP professional in the Pharma and Biotech industry, Fredrik has learnt to use this IPR toolbox to pursue his professional passion; maximizing return on investment for innovation.”

Author:

Lorenz Kallenbach

Senior Corporate Patent Counsel
Merck

Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.

Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.

Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.

Lorenz Kallenbach

Senior Corporate Patent Counsel
Merck

Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.

Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.

Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.

Author:

Stephan Kutik

IP Lead for Nephrology and Orphan Drugs
Vifor Pharma

Stephan Kutik

IP Lead for Nephrology and Orphan Drugs
Vifor Pharma

Author:

Frank Landolt

Chief Counsel, Intellectual Property and Legal
Confo Therapeutics

Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.

After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechnological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.

Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi, and Wyeth.

From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto, and DuPont Pioneer.

Frank is a Dutch and European patent attorney and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI, and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).

Frank Landolt

Chief Counsel, Intellectual Property and Legal
Confo Therapeutics

Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.

After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechnological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.

Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi, and Wyeth.

From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto, and DuPont Pioneer.

Frank is a Dutch and European patent attorney and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI, and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).

Author:

Nicolas Pourbaix

Senior Counsel
Amgen

Nicolas Pourbaix

Senior Counsel
Amgen

Author:

Dean Thomas

Global Head of IP and Associate General Cousel
Ichnos Sciences

An experienced life sciences IP lawyer with more than 20 years of experience in house and private practice, throughout Europe. 

Dean Thomas

Global Head of IP and Associate General Cousel
Ichnos Sciences

An experienced life sciences IP lawyer with more than 20 years of experience in house and private practice, throughout Europe. 

Author:

Alexandra Moulson

VP Development
Polpharma Biologics

Alex is an experienced leader and strategist with a broad background in marketing, product development, business development, portfolio management, and launch.

She has over 18 years of experience in pharmaceuticals, 8 years originators, 8 years biosimilars, and 2 years generics. Alex is British, with Biochemistry and MBA degrees.

Working backward, following her MBA, Alex was at McKinsey (reaching Associate Principal), at Morphosys was the Director for Business Development and at Sandoz brought a rituximab biosimilar to market and later led the Strategy Department for Sandoz. She is currently the Chief Development Officer for Polpharma Biologics.

Alexandra Moulson

VP Development
Polpharma Biologics

Alex is an experienced leader and strategist with a broad background in marketing, product development, business development, portfolio management, and launch.

She has over 18 years of experience in pharmaceuticals, 8 years originators, 8 years biosimilars, and 2 years generics. Alex is British, with Biochemistry and MBA degrees.

Working backward, following her MBA, Alex was at McKinsey (reaching Associate Principal), at Morphosys was the Director for Business Development and at Sandoz brought a rituximab biosimilar to market and later led the Strategy Department for Sandoz. She is currently the Chief Development Officer for Polpharma Biologics.

be the first to receive the 2023 agenda

Please fill in your details to register your interest for the 2023 conference.

 

Register Your Interest for 2023

Who ATTENDED in 2022

50%
Industry In-House
40%
Law Firms
10%
Vendors/CDMOs

Industry In-House

Law Firms

Vendors/CDMOs

Our 2022 Legal Portfolio Partners Include

.

2022 speakers

 

Emmanuel Gougé

Partner
Pinsent Masons

Emmanuel Gougé is a renowned counsel and litigator in IP law, with a strong focus on patents, trade secrets and trademarks. Emmanuel has been involved in a range of multi-jurisdictional IP matters. His practice focuses mainly on electronics, automotive, aerospace, life sciences, and medical devices. Emmanuel has been involved in a wide range of cross-border litigations and has played an instrumental role in advising clients on multi-jurisdictional matters.

Emmanuel Gougé

Partner
Pinsent Masons

Emmanuel Gougé

Partner
Pinsent Masons

Emmanuel Gougé is a renowned counsel and litigator in IP law, with a strong focus on patents, trade secrets and trademarks. Emmanuel has been involved in a range of multi-jurisdictional IP matters. His practice focuses mainly on electronics, automotive, aerospace, life sciences, and medical devices. Emmanuel has been involved in a wide range of cross-border litigations and has played an instrumental role in advising clients on multi-jurisdictional matters.

 

Catherine Drew

Partner
Pinsent Masons

Catherine Drew

Partner
Pinsent Masons

Catherine Drew

Partner
Pinsent Masons
 

Alexandra Moulson

VP Development
Polpharma Biologics

Alex is an experienced leader and strategist with a broad background in marketing, product development, business development, portfolio management, and launch.

She has over 18 years of experience in pharmaceuticals, 8 years originators, 8 years biosimilars, and 2 years generics. Alex is British, with Biochemistry and MBA degrees.

Alexandra Moulson

VP Development
Polpharma Biologics

Alexandra Moulson

VP Development
Polpharma Biologics

Alex is an experienced leader and strategist with a broad background in marketing, product development, business development, portfolio management, and launch.

She has over 18 years of experience in pharmaceuticals, 8 years originators, 8 years biosimilars, and 2 years generics. Alex is British, with Biochemistry and MBA degrees.

Working backward, following her MBA, Alex was at McKinsey (reaching Associate Principal), at Morphosys was the Director for Business Development and at Sandoz brought a rituximab biosimilar to market and later led the Strategy Department for Sandoz. She is currently the Chief Development Officer for Polpharma Biologics.

 

Christof Bull

Assistant General Patent Counsel
UCB

Christof Bull

Assistant General Patent Counsel
UCB

Christof Bull

Assistant General Patent Counsel
UCB
 

Dean Thomas

Global Head of IP and Associate General Cousel
Ichnos Sciences

An experienced life sciences IP lawyer with more than 20 years of experience in house and private practice, throughout Europe. 

Dean Thomas

Global Head of IP and Associate General Cousel
Ichnos Sciences

Dean Thomas

Global Head of IP and Associate General Cousel
Ichnos Sciences

An experienced life sciences IP lawyer with more than 20 years of experience in house and private practice, throughout Europe. 

 

Dr. Leslie Fischer

Principal Patent Attorney
Sandoz

Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage.

Dr. Leslie Fischer

Principal Patent Attorney
Sandoz

Dr. Leslie Fischer

Principal Patent Attorney
Sandoz

Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.

 

Ha Kung Wong

Partner, Advisory Board Member
Venable, Centre for Biosimilars

Ha Kung Wong has over 20 years of experience practicing general intellectual property law with an emphasis on complex patent and trade secret litigation as well as IP transactions and contract negotiations for mergers, acquisitions, and collaborations in pharmaceuticals, biologics, and chemistry. Cases Mr. Wong has litigated include those related to proton pump inhibitors, allergy eye drops, anti-epileptic drugs, anti-tussive, injectable microspheres, RNAi products, and other pharmaceuticals. Mr.

Ha Kung Wong

Partner, Advisory Board Member
Venable, Centre for Biosimilars

Ha Kung Wong

Partner, Advisory Board Member
Venable, Centre for Biosimilars

Ha Kung Wong has over 20 years of experience practicing general intellectual property law with an emphasis on complex patent and trade secret litigation as well as IP transactions and contract negotiations for mergers, acquisitions, and collaborations in pharmaceuticals, biologics, and chemistry. Cases Mr. Wong has litigated include those related to proton pump inhibitors, allergy eye drops, anti-epileptic drugs, anti-tussive, injectable microspheres, RNAi products, and other pharmaceuticals. Mr. Wong also has extensive experience with Inter Partes Review, Post Grant Review, intellectual property counseling, pharmaceutical regulatory counseling, pre-suit investigations, licensing, and due diligence.

Mr. Wong has his BS with high distinction in Chemistry and his BS in Biochemistry from the University of Illinois Urbana-Champaign and his JD, cum laude, from the University of Notre Dame. Mr. Wong is currently an elected member of the Venable Board, is an Advisory Board Member for the Center for Biosimilars, is Treasurer, Executive Committee member, and Board Trustee for the Foundation for Advancement of Diversity in IP Law (FADIPL) and serves as faculty for the National Institute of Trial Advocacy (NITA) and Lawline.

 

Nicholas Pourbaix

Amgen

Nicholas Pourbaix

Amgen

Nicholas Pourbaix

Amgen
 

Xisca Borrás

Partner
Bristow (UK)

Xisca Borrás

Partner
Bristow (UK)

Xisca Borrás

Partner
Bristow (UK)
 

Nikki Jessop

National Biosimilar and Speciality Commercial Lead
Zentiva

Nikki Jessop

National Biosimilar and Speciality Commercial Lead
Zentiva

Nikki Jessop

National Biosimilar and Speciality Commercial Lead
Zentiva
 

Oliver Lemaire

General Counsel and Compliance Officer
Ziphius Vaccines

Oliver Lemaire

General Counsel and Compliance Officer
Ziphius Vaccines

Oliver Lemaire

General Counsel and Compliance Officer
Ziphius Vaccines
 

Paul Csiszar

DG Competition
European Commission

After graduating from ELTE School of Law of Budapest, Paul Csiszár studied international comparative law and earned a second Juris Doctorate at Loyola Law School in the United States. Following his admission to the California Bar in 1986 he practiced as a corporate, securities and M&A lawyer in the US and then from 1997 in Europe with the international law firm of Squire Sanders until 2003 when he joined the public sector. Currently Mr Csiszár serves as one of the Directors of the Directorate General for Competition of the European Commission.

Paul Csiszar

DG Competition
European Commission

Paul Csiszar

DG Competition
European Commission

After graduating from ELTE School of Law of Budapest, Paul Csiszár studied international comparative law and earned a second Juris Doctorate at Loyola Law School in the United States. Following his admission to the California Bar in 1986 he practiced as a corporate, securities and M&A lawyer in the US and then from 1997 in Europe with the international law firm of Squire Sanders until 2003 when he joined the public sector. Currently Mr Csiszár serves as one of the Directors of the Directorate General for Competition of the European Commission.

 

Sam Granata

Judge
Court Appeal Antwarp

Sam Granata

Judge
Court Appeal Antwarp

Sam Granata

Judge
Court Appeal Antwarp
 

Tamaris Bucher

Principal Patent Attorney
Novartis

Tamaris is a Principal Patent Attorney at Novartis. She has gained extensive experience in pharmaceuticals in her almost ten years at Novartis, as well as from a previous role at a patent law firm in Basel.

She specialises in patent matters relating to antibody technology and cell & gene therapies. She has expertise in patent prosecution and SPC issues, as well as a keen interest in following legal developments in these areas.

Tamaris Bucher

Principal Patent Attorney
Novartis

Tamaris Bucher

Principal Patent Attorney
Novartis

Tamaris is a Principal Patent Attorney at Novartis. She has gained extensive experience in pharmaceuticals in her almost ten years at Novartis, as well as from a previous role at a patent law firm in Basel.

She specialises in patent matters relating to antibody technology and cell & gene therapies. She has expertise in patent prosecution and SPC issues, as well as a keen interest in following legal developments in these areas.

Tamaris is both a registered European Patent Attorney and Swiss Patent Attorney. Additionally, she has a background in Australian patent law, having completed a Master of Industrial Property at the University of Technology, Sydney.

 

Julia Pike

Global Head of IP
Sandoz

Since March 2020, Julia has been the Global Head of IP for Sandoz. In her previous roles with Sandoz, she has had a leading role in the first wave of US biosimilars litigation, including the first litigations on critical aspects of the governing legislation (the Biologics Price Competition and Innovation Act or BPCIA), culminating in the landmark US Supreme Court decision, Sandoz v Amgen.

 

Julia Pike

Global Head of IP
Sandoz

Julia Pike

Global Head of IP
Sandoz

Since March 2020, Julia has been the Global Head of IP for Sandoz. In her previous roles with Sandoz, she has had a leading role in the first wave of US biosimilars litigation, including the first litigations on critical aspects of the governing legislation (the Biologics Price Competition and Innovation Act or BPCIA), culminating in the landmark US Supreme Court decision, Sandoz v Amgen.

 

Since leaving private practice at Corrs Chambers Westgarth, Julia has been in-house counsel for many years including at Mayne Pharma and Hospira Inc before joining Sandoz in 2008. While there, she has taken on roles in European public affairs and led Sandoz’s global IP litigation function as Global Head of IP Litigation. Through those roles, she has maintained a keen interest in IP strategy and litigation worldwide, including cases arising under the Hatch-Waxman and BPCIA legislation in the US, PM(NOC) regulations in Canada and litigation arising from patent linkage systems around the world. 

 

Katie Hyma

Associate
FISH & RICHARDSON P.C

Katie Hyma

Associate
FISH & RICHARDSON P.C

Katie Hyma

Associate
FISH & RICHARDSON P.C
 

Hilary Jones

Senior Director Legal Pharmaceutical Regulation
BioNTech

Hilary Jones

Senior Director Legal Pharmaceutical Regulation
BioNTech

Hilary Jones

Senior Director Legal Pharmaceutical Regulation
BioNTech
 

Robert Cerwinski

Managing Partner
Gemini Law

Rob Cerwinski, managing partner, is a seasoned patent litigator and IP strategist with 20+ years of experience at premier U.S. law firms helping international clients launch biopharma products into the highly-competitive U.S. market. Mr. Cerwinski specializes in helping companies devise cost-effective strategies to navigate the complex and intertwined legal, regulatory and financial hurdles that can delay or prevent product launch. His successes in pre-litigation strategy and in the courtroom have driven the launch of 20+ biopharma products in the U.S. and Europe. Mr.

Robert Cerwinski

Managing Partner
Gemini Law

Robert Cerwinski

Managing Partner
Gemini Law

Rob Cerwinski, managing partner, is a seasoned patent litigator and IP strategist with 20+ years of experience at premier U.S. law firms helping international clients launch biopharma products into the highly-competitive U.S. market. Mr. Cerwinski specializes in helping companies devise cost-effective strategies to navigate the complex and intertwined legal, regulatory and financial hurdles that can delay or prevent product launch. His successes in pre-litigation strategy and in the courtroom have driven the launch of 20+ biopharma products in the U.S. and Europe. Mr. Cerwinski holds a Master of Science Degree in molecular biology and has a deep understanding of the science, business and regulation of biopharma product development, manufacture and marketing. Mr. Cerwinski co-founded the industry-leading biosimilars practice at Goodwin Procter LLP and is a recognized global authority on biosimilars. He is Senior Editor of the leading legal treatise in the field, Guide to Biosimilars Litigation and Regulation in the U.S. (published by Thomson-Reuters) and founded Goodwin’s award-winning biosimilars blog, Big Molecule Watch and its companion blog, Big Molecule Watch China. Mr. Cerwinski was named an IAM Global Leader in Intellectual Property Law in 2021 and is ranked in the Gold Tier of the IAM Patent 1000. 

 

Emmanuele Degortes

Global Head of Patient, Innovation and Access Policy
Vifor Pharma

Emanuele is the Global Head of Patient, Innovation and Access Policy at Vifor Pharma, a global pharmaceutical company headquartered in Switzerland, specialized in iron deficiency, nephrology and rare conditions. In his role, Emanuele coordinates the company’s government affairs and patient advocacy engagement at EU, international and country level. Previously Emanuele led Biogen’s European Public Policy and Government Affairs activities and was a Director in the Healthcare Practice of FTI Consulting.

Emmanuele Degortes

Global Head of Patient, Innovation and Access Policy
Vifor Pharma

Emmanuele Degortes

Global Head of Patient, Innovation and Access Policy
Vifor Pharma

Emanuele is the Global Head of Patient, Innovation and Access Policy at Vifor Pharma, a global pharmaceutical company headquartered in Switzerland, specialized in iron deficiency, nephrology and rare conditions. In his role, Emanuele coordinates the company’s government affairs and patient advocacy engagement at EU, international and country level. Previously Emanuele led Biogen’s European Public Policy and Government Affairs activities and was a Director in the Healthcare Practice of FTI Consulting. In his spare time he runs a film festival on a deserted island off the coast of Sardinia. 

 

Sharada Devarasetty

Head of Biopharmaceuticals Patents
Sandoz

Sharada has spent the last decade building global IP strategies to launch biosimilars.  She started her career in the US with the patent litigation group at Proskauer Rose, participating in several ITC litigations in addition to her district court docket.  In 2012, she moved to Boehringer Ingelheim to begin her career in the then-new and exciting biosimilars market.  There she helped build strategies for most of the first wave biosimilar, in addition to advising her client how to prepare for global biosimilar litigation.  More recently, she leads the biosimilar IP team at Sandoz, a global l

Sharada Devarasetty

Head of Biopharmaceuticals Patents
Sandoz

Sharada Devarasetty

Head of Biopharmaceuticals Patents
Sandoz

Sharada has spent the last decade building global IP strategies to launch biosimilars.  She started her career in the US with the patent litigation group at Proskauer Rose, participating in several ITC litigations in addition to her district court docket.  In 2012, she moved to Boehringer Ingelheim to begin her career in the then-new and exciting biosimilars market.  There she helped build strategies for most of the first wave biosimilar, in addition to advising her client how to prepare for global biosimilar litigation.  More recently, she leads the biosimilar IP team at Sandoz, a global leader in biosimilars, for the next wave of launches.

 

Frank Landolt

Chief Counsel, Intellectual Property and Legal
Confo Therapeutics

Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.

After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechnological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.

Frank Landolt

Chief Counsel, Intellectual Property and Legal
Confo Therapeutics

Frank Landolt

Chief Counsel, Intellectual Property and Legal
Confo Therapeutics

Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.

After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechnological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.

Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi, and Wyeth.

From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto, and DuPont Pioneer.

Frank is a Dutch and European patent attorney and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI, and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).

 

Julia Pike

Global Head of IP
Sandoz

Since March 2020, Julia has been the Global Head of IP for Sandoz. In her previous roles with Sandoz, she has had a leading role in the first wave of US biosimilars litigation, including the first litigations on critical aspects of the governing legislation (the Biologics Price Competition and Innovation Act or BPCIA), culminating in the landmark US Supreme Court decision, Sandoz v Amgen.

 

Julia Pike

Global Head of IP
Sandoz

Julia Pike

Global Head of IP
Sandoz

Since March 2020, Julia has been the Global Head of IP for Sandoz. In her previous roles with Sandoz, she has had a leading role in the first wave of US biosimilars litigation, including the first litigations on critical aspects of the governing legislation (the Biologics Price Competition and Innovation Act or BPCIA), culminating in the landmark US Supreme Court decision, Sandoz v Amgen.

 

Since leaving private practice at Corrs Chambers Westgarth, Julia has been in-house counsel for many years including at Mayne Pharma and Hospira Inc before joining Sandoz in 2008. While there, she has taken on roles in European public affairs and led Sandoz’s global IP litigation function as Global Head of IP Litigation. Through those roles, she has maintained a keen interest in IP strategy and litigation worldwide, including cases arising under the Hatch-Waxman and BPCIA legislation in the US, PM(NOC) regulations in Canada and litigation arising from patent linkage systems around the world. 

 

Chad Shear

Principal
Fish & Richardson (USA)

Chad is a principal in the firm’s San Diego office and is the go-to patent litigator for numerous multinational life sciences companies — including Gilead, GSK, iCeutica, Iroko, Coherus Biosciences and Dainippon Sumitomo Pharma — whose marquee products deliver billions of dollars in annual revenues. He draws on his litigation experience, extensive network of scientific and business experts, and detailed knowledge of his clients’ companies to provide strategic legal counsel on a wide range of business matters.

Chad Shear

Principal
Fish & Richardson (USA)

Chad Shear

Principal
Fish & Richardson (USA)

Chad is a principal in the firm’s San Diego office and is the go-to patent litigator for numerous multinational life sciences companies — including Gilead, GSK, iCeutica, Iroko, Coherus Biosciences and Dainippon Sumitomo Pharma — whose marquee products deliver billions of dollars in annual revenues. He draws on his litigation experience, extensive network of scientific and business experts, and detailed knowledge of his clients’ companies to provide strategic legal counsel on a wide range of business matters. With extensive global experience, including serving as lead attorney in complex patent proceedings, trials and appeals across Asia, Europe, North America, and Australia, Chad has proven to be a results-focused, hands-on leader known for assembling and managing effective, collaborative teams across multiple time zones, firms, and languages.

 

Nadia Spiccia

Associate
KIRKLAND & ELLIS INTERNATIONAL LLP

Nadia Spiccia is an associate in Kirkland’s Intellectual Property Litigation Practice Group in London. Nadia’s practice focuses on complex cross border and multijurisdictional life sciences patent disputes requiring significant coordination across multiple forums at both first instance and on appeal. With over 12 years’ experience supporting global pharma/biopharma and a background in chemistry, Nadia leverages her legal and technical experience to provide strategic counselling.

Nadia Spiccia

Associate
KIRKLAND & ELLIS INTERNATIONAL LLP

Nadia Spiccia

Associate
KIRKLAND & ELLIS INTERNATIONAL LLP

Nadia Spiccia is an associate in Kirkland’s Intellectual Property Litigation Practice Group in London. Nadia’s practice focuses on complex cross border and multijurisdictional life sciences patent disputes requiring significant coordination across multiple forums at both first instance and on appeal. With over 12 years’ experience supporting global pharma/biopharma and a background in chemistry, Nadia leverages her legal and technical experience to provide strategic counselling. Prior to joining Kirkland, Nadia was Head of Patent Litigation - ex NA at Sandoz responsible for the launch and litigation of Sandoz’s small molecule and biosimilars worldwide apart from North America. Prior to this Nadia was Head of Legal and Company Secretary - ANZ for Mylan (now Viatris). Nadia was recognised by Managing IP as a Notable Practitioner in the 2021 edition of its IP Stars guide and as a Corporate IP Star – Europe in the 2019-2020 editions. She was also named to the list of Leading In-House Intellectual Property & TMT Lawyers – Australia by Doyle’s Guide in the 2019-2020 editions.

 

Shohta Ueno

Director, Dispute Resolution
Regeneron

Dr Shohta Ueno is a Director, Dispute Resolution at Regeneron Pharmaceuticals Inc., a leading biopharmaceutical company where he advises the company on a broad range of complex, multi-jurisdictional disputes.  While Shohta deals with all matters relating to disputes, he focuses mostly on non-US IP matters and helps the company navigate through increasingly complex IP landscape.  Shohta joined Regeneron in October 2018 from a leading IP litigation practice based in the UK.  Shohta is also a trained scientist – he obtained a PhD in Virology as well as an undergraduate degree in Natural Scienc

Shohta Ueno

Director, Dispute Resolution
Regeneron

Shohta Ueno

Director, Dispute Resolution
Regeneron

Dr Shohta Ueno is a Director, Dispute Resolution at Regeneron Pharmaceuticals Inc., a leading biopharmaceutical company where he advises the company on a broad range of complex, multi-jurisdictional disputes.  While Shohta deals with all matters relating to disputes, he focuses mostly on non-US IP matters and helps the company navigate through increasingly complex IP landscape.  Shohta joined Regeneron in October 2018 from a leading IP litigation practice based in the UK.  Shohta is also a trained scientist – he obtained a PhD in Virology as well as an undergraduate degree in Natural Sciences from the University of Cambridge. 

 

Geneviève Michaux

Partner | FDA and Life Sciences
King & Spalding (BEL)

Geneviève Michaux

Partner | FDA and Life Sciences
King & Spalding (BEL)

Geneviève Michaux

Partner | FDA and Life Sciences
King & Spalding (BEL)
 

Beatriz Díaz de Escauriaza

Head of IP Legal
Insud Pharma

Beatriz is currently Head of the IP Legal Practice at Insud Pharma Group, a diversified biopharmaceutical business based in Madrid, Spain, that she joined in 2017. Beatriz holds a degree in Law and a Master Degree in Intellectual Property by the University of Alicante (Magister Lvcentinvs). Before joining Insud Pharma, Beatriz worked in private practice as a patent litigator in Madrid with Bird & Bird where she specialized on pharma patent litigation.

Beatriz Díaz de Escauriaza

Head of IP Legal
Insud Pharma

Beatriz Díaz de Escauriaza

Head of IP Legal
Insud Pharma

Beatriz is currently Head of the IP Legal Practice at Insud Pharma Group, a diversified biopharmaceutical business based in Madrid, Spain, that she joined in 2017. Beatriz holds a degree in Law and a Master Degree in Intellectual Property by the University of Alicante (Magister Lvcentinvs). Before joining Insud Pharma, Beatriz worked in private practice as a patent litigator in Madrid with Bird & Bird where she specialized on pharma patent litigation. During her years at Bird&Bird she also intervened before the European authorities, having also acted before the European Court of Justice at Strasbourg.

Our Life Sciences Legal Portfolio Attendees Include

Partner With Us

Based on your objectives, we can create bespoke packages designed specifically for you – from presenting your expertise on the main stage, to hosting a private dinner. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.

To discuss your objectives and partnership opportunities please contact [email protected]

DOWNLOAD SPEX PROSPECTUS

Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us